Z82.41 Insurance Policy Changes

ICD-10 Z82.41 is officially defined as "Family history of sudden cardiac death." code Z82.41 is referenced in 7 tracked payer policy changes from Blue Cross & Blue Shield of Mississippi, Excellus BlueCross BlueShield, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code Z82.41 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Blue Cross & Blue Shield of Mississippi · Effective Oct 1, 2026Medium impact
Genetic Testing for Cardiac Ion Channelopathies
Genetic testing for long QT syndrome, CPVT, Brugada syndrome and short QT syndrome may be considered medically necessary only in the situations the policy lists. For symptomatic individuals, testing may be considered when a definitive diagnosis cannot be made without it, and for long QT syndrome this includes individuals with a Schwartz score below 4 but a moderate-to-high pretest probability. For asymptomatic individuals, testing may be considered only when a close relative has a known variant, or, for long QT syndrome and CPVT, when a close relative was diagnosed clinically and genetic status is unavailable, and all other testing is considered investigational.
Excellus BlueCross BlueShield · Effective May 21, 2026Medium impact
Genetic Testing for Cardiac Ion Channelopathies 2.02.38
Excellus BlueCross BlueShield medical policy 2.02.38, Genetic Testing for Cardiac Ion Channelopathies, has a current effective date of May 21, 2026, and its annual review on that date left the policy intent unchanged. Genetic testing for congenital long QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT) and Brugada syndrome is medically appropriate when signs or symptoms are present but a definitive diagnosis cannot be made without it, or for at-risk individuals who have a qualifying first-, second- or third-degree relative, in each case only when the test results will influence treatment decisions. Genetic testing to determine future risk of short QT syndrome (SQTS) is medically appropriate for asymptomatic individuals who have a first-, second- or third-degree relative with a known SQTS variant.
Aetna · Identified Oct 4, 2026Medium impact
Genetic Testing (CPB 0140, reviewed 2026-08-18)
Aetna covers genetic testing only when the criteria for the specific condition are met, and it considers testing outside those criteria experimental, investigational, or unproven, including testing for Parkinson disease, essential tremor, coronary artery disease (except testing for familial hypercholesterolemia), and type 2 diabetes other than MODY. Multi-gene panels for inherited cancers are covered only for members with a personal or family history of a related cancer when more than one inherited cancer syndrome could explain the presentation and the panel is more efficient than separate tests, and genetic testing for inherited cancers is a once-in-a-lifetime benefit. Expanded carrier screening for people who are pregnant or planning a pregnancy is covered when the panel includes cystic fibrosis, spinal muscular atrophy, and/or hemoglobinopathies, unless previously performed, and the results will be used in managing the pregnancy or for family planning; whole exome or whole genome sequencing is covered for an unexplained congenital or neurodevelopmental disorder when its listed criteria are met, and whole genome sequencing after a non-diagnostic whole exome test is considered not medically necessary.
Aetna · Identified Sep 30, 2026Medium impact
Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) (CPB 0558, reviewed 2026-08-21)
Aetna considers alcohol septal ablation (PTSMA) medically necessary for adults 21 years of age and older with hypertrophic obstructive cardiomyopathy when all listed criteria are met, including a clinical diagnosis of hypertrophic cardiomyopathy by echocardiography or cardiovascular MRI, severe symptoms that interfere with activities of daily living despite optimal drug therapy, NYHA functional class III or IV, and a peak LVOT gradient of 50 mm Hg or more. Aetna also considers PTSMA medically necessary for carefully selected members aged 5 to 20 with HOCM who meet separate pediatric criteria, and considers PTSMA for all other indications, SESAME, and ultrasound-guided PTSMA experimental, investigational, or unproven.
Aetna · Identified Aug 13, 2026Medium impact
Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) (CPB 0558, reviewed 2026-02-19)
Aetna Clinical Policy Bulletin 0558 considers percutaneous transluminal septal myocardial ablation (PTSMA) by alcohol-induced septal branch occlusion medically necessary for hypertrophic obstructive cardiomyopathy (HOCM) in adults 21 years of age and older when all listed criteria are met, including severe symptoms despite optimal drug therapy, NYHA class III or IV, a peak LVOT gradient of at least 50 mm Hg, and suitable coronary anatomy with an identifiable septal perforator artery. Aetna also considers PTSMA medically necessary for carefully selected members 5 to 20 years of age with HOCM when the pediatric criteria are met, and it considers PTSMA for all other indications, SESAME, and ultrasound-guided PTSMA experimental, investigational, or unproven.
Independence Blue Cross · Identified Jun 19, 2026Low impact
06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)
This is a routine annual reissue of Independence Administrators' genetic testing policy for congenital Long QT Syndrome with no substantive changes to coverage criteria or billing codes. The policy clarifies that it applies only to members whose groups have NOT enrolled in the UM vendor program; groups with UM vendor enrollment should refer to the eviCore Lab Management Program instead.
Independence Blue Cross · Identified Jun 19, 2026Low impact
06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)
This is a reissue of policy 06.02.31g with no substantive changes to coverage criteria for genetic testing of congenital Long QT Syndrome. The only modification is clarification of the applicability disclaimer: the policy now explicitly excludes groups enrolled in the UM vendor program, replacing the previous reference to eviCore Lab Management Program. Billing teams should verify member eligibility and UM vendor enrollment status before processing genetic testing claims.

Watch Z82.41

Get one email when a payer policy names Z82.41, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code Z82.41?

There are 7 tracked policy changes affecting code Z82.41, including updates from Blue Cross & Blue Shield of Mississippi, Excellus BlueCross BlueShield, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code Z82.41?

Payers that have issued tracked updates for code Z82.41 include: Blue Cross & Blue Shield of Mississippi, Excellus BlueCross BlueShield, Aetna, Independence Blue Cross.

How do I get notified when code Z82.41 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code Z82.41. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code Z82.41?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Genetic Testing for Cardiac Ion Channelopathies

Genetic Testing for Cardiac Ion Channelopathies 2.02.38

Genetic Testing (CPB 0140, reviewed 2026-08-18)

Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) (CPB 0558, reviewed 2026-08-21)

Percutaneous Transluminal Septal Myocardial Ablation (PTSMA) (CPB 0558, reviewed 2026-02-19)

06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)

06.02.31g, Genetic Testing for Congenital Long QT Syndrome (Independence Administrators)

What insurance policy changes affect code Z82.41?

Which payers have updated policy for code Z82.41?

How do I get notified when code Z82.41 policy changes?

Why do payers change policies for code Z82.41?